HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis

María‐Victoria Mateos , Xavier Leleu + Show 20 more

Open Access

https://doi.org/10.1182/blood-2020-136002

Copy DOI

Export

Save

Share

Cite

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 3

Affiliation: Instituto de Investigación Biomédica de Salamanca, Centre Hospitalier Universitaire de Poitiers, Institut Català d'Oncologia, Dana-Farber Cancer Institute, Harvard University, Rush University Medical Center, University of Pittsburgh, Oncology Institute of Hope and Innovation, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Nantes Université, Inserm, French National Centre for Scientific Research, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Centre Hospitalier Universitaire de Nantes, University of Angers, Baptist Cancer Center, Baylor Medical Center at Garland, Hospital Universitario Quirónsalud Madrid, University of Florida, Memorial Sloan Kettering Cancer Center, Oncopeptides (Sweden), University of Bologna, Clinica Universidad de Navarra, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

#Advisory Committees #Equity Holder In Publicly-traded Company #Current Equity Holder #Speakers Bureau #Entity's Board #Publicly-traded Company #Private Company #Board Of Directors #Research Funding #Relapsed/refractory Multiple Myeloma

Abstract
Full-Text
Similar Papers

Abstract

HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.